

Gene expression

# FORESEE: a tool for the systematic comparison of translational drug response modeling pipelines

Lisa-Katrin Turnhoff <sup>1,2,\*</sup>, Ali Hadizadeh Esfahani <sup>1,2,†</sup>,  
Maryam Montazeri <sup>1,2</sup>, Nina Kusch <sup>1,2</sup> and Andreas Schuppert <sup>1,2,\*</sup>

<sup>1</sup>Joint Research Center for Computational Biomedicine (JRC-COMBINE), RWTH Aachen University, 52074 Aachen, Germany and <sup>2</sup>Aachen Institute for Advanced Study in Computational Engineering Science (AICES), RWTH Aachen University, 52062 Aachen, Germany

\*To whom correspondence should be addressed.

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.

Associate Editor: Janet Kelso

Received on June 11, 2018; revised on February 11, 2019; editorial decision on February 20, 2019; accepted on February 25, 2019

## Abstract

**Summary:** Translational models that utilize *omics* data generated in *in vitro* studies to predict the drug efficacy of anti-cancer compounds in patients are highly distinct, which complicates the benchmarking process for new computational approaches. In reaction to this, we introduce the uniFied translatiOnal dRug rESponse prEdiction platform FORESEE, an open-source R-package. FORESEE not only provides a uniform data format for public cell line and patient datasets, but also establishes a standardized environment for drug response prediction pipelines, incorporating various state-of-the-art pre-processing methods, model training algorithms and validation techniques. The modular implementation of individual elements of the pipeline facilitates a straightforward development of combinatorial models, which can be used to re-evaluate and improve already existing pipelines as well as to develop new ones.

**Availability and implementation:** FORESEE is licensed under GNU General Public License v3.0 and available at <https://github.com/JRC-COMBINE/FORESEE> and <https://doi.org/10.17605/OSF.IO/RF6QK>, and provides vignettes for documentation and application both online and in the Supplementary Files 2 and 3.

**Contact:** [turnhoff@combine.rwth-aachen.de](mailto:turnhoff@combine.rwth-aachen.de) or [schuppert@combine.rwth-aachen.de](mailto:schuppert@combine.rwth-aachen.de)

**Supplementary information:** [Supplementary data](#) are available at *Bioinformatics* online.

## 1 Introduction

Cell line data bases featuring both multi-omics characterizations of human cancer cell lines and their response profiles to drug compounds have become a vital tool in developing predictive drug response models for cancer patients. Concomitant with their advancement, tools have been developed to provide access to the data (Luna *et al.*, 2016; Smirnov *et al.*, 2016) and to systematically evaluate models for drug response prediction (Jang *et al.*, 2014). In order to attain clinical relevance, such cell line-based models need to be translated and tested on patient data, which has become the

focus of a steadily growing number of studies: while some are restricted to gene expression data (Geeleher *et al.*, 2014; Huang *et al.*, 2017), other studies additionally incorporate mutation profiles and copy number variations (Dorman *et al.*, 2016), promoter methylation (Aben *et al.*, 2016) and protein expression (Daemen *et al.*, 2013). As a consequence of the diversity and scope of the work that has been performed in this field, comparing the various approaches is complicated and the process of benchmarking novel computational methods has become time-consuming. In order to address this, we introduce the FORESEE platform to facilitate a

straightforward and comprehensive evaluation of translational drug response models.

## 2 Implementation

For the systematic evaluation of individual components of the modeling pipeline and their impact on the performance, the FORESEE package features not only functional elements of the pipeline, but also introduces a common data format for frequently used data resources. Thus, it allows for the methodical investigation of all possible combinations of modeling choices, as well as for testing a specific pipeline on different datasets, thereby exploring how the choice of data affects modeling performance.

### 2.1 Data


Supporting the idea of translational modeling pipelines, the FORESEE package comprises molecular and pharmacological data that characterize cell lines, xenografts and patients. In terms of cell line characterization, data from the Genomics of Drug Sensitivity in Cancer (Garnett *et al.*, 2012), the Cancer Cell Line Encyclopedia (Barretina *et al.*, 2012; Cancer Cell Line Encyclopedia Consortium and Genomics of Drug Sensitivity in Cancer Consortium, 2015), the Cancer Therapeutics Response Portal (Basu *et al.*, 2013; Rees *et al.*, 2016; Seashore-Ludlow *et al.*, 2015) and Daemen *et al.* (2013) were formatted into *ForeseeCell* objects. Each of these *ForeseeCell* objects contain at least one type of molecular data, such as gene expression, and one type of pharmacological data, such as the IC<sub>50</sub> (half maximal inhibitory concentration). On the other hand, information of patients with breast cancer [GSE6434 (Chang *et al.*, 2005) and GSE18864 (Silver *et al.*, 2010)], lung cancer [GSE33072 (Byers *et al.*, 2013)], ovarian cancer [GSE51373 (Koti *et al.*, 2013)] and multiple myeloma [GSE9782 (Mulligan *et al.*, 2007)] was organized into *ForeseePatient* objects including at least one molecular data type and one measure of *in vivo* drug efficacy, such as tumor shrinkage. Although primarily developed to design translational models that are trained on cell line data and tested on patient data, FORESEE also allows for testing cell line-trained models on other cell line datasets. Moreover, data from patient derived xenografts (Gao *et al.*, 2015; Witkiewicz *et al.*, 2016), bridging the differences between cell lines and patients, were included as *ForeseeCell* objects to offer a supplementary translational modeling opportunity: testing patient derived xenografts-trained models on patients. A detailed description of how the data were obtained and prepared can be found in [Supplementary File 2](#).

### 2.2 Pipeline

The functional elements of the modeling pipeline, which are depicted in [Figure 1](#) and explained in more detail in [Supplementary File 1](#), are implemented as independent modules that can be changed individually, according to the user's preferences. Across all main steps of the pipeline, user-defined functions can substitute the pre-implemented methods to enable a more flexible use of the package, which is explained in [Supplementary File 3](#) along with other use cases.

## 3 Discussion

The FORESEE R-package is designed to explore and compare translational drug response models. Thus, it comprises both a standardized data format for molecular *in vitro* and *in vivo* data and functional building blocks that summarize various well-established pre-processing and processing options. Moreover, each of the functional blocks allows for the application of user-defined alternatives



**Fig. 1.** Illustration of the general FORESEE pipeline. The modeling routine comprises two main shells, *ForeseeTrain* (upper loop) and *ForeseeTest* (lower loop), with each consisting of different functional elements (boxes). During training, molecular cell line data are pre-processed by selecting certain samples in *SampleSelector*, removing duplicated feature names in *DuplicationHandler*, reducing batch effects in *Homogenizer*, selecting certain features in *FeatureSelector*, transforming the data in *FeaturePreprocessor* and combining the different molecular data types in *FeatureCombiner*, while the response data are transformed in *CellResponseProcessor*. The pre-processed data are then used for model training in *BlackBoxFilter*. The *Foreseer* applies the completed model to molecular patient data that have been pre-processed in the same manner as the cell line data to yield a prediction for patient drug sensitivity, which is subsequently compared to the actual response in *Validator* to evaluate the overall performance of the translational model

to support the fast and easy development of novel modeling pipelines. Future expansions of FORESEE are directed toward an automatic optimization for identifying the modeling pipeline best-suited for a particular setting. Until then, we hope that FORESEE can facilitate exchanging expertise among researchers by providing a standard environment for translational drug sensitivity models and therefore push forward the potential to predict drug sensitivity of cancer patients.

## Acknowledgements

We thank Jérôme Schätzle for his assistance in creating the figure and testing the package, and Pejman Farhadi for proof-reading the manuscript.

## Funding

This work was partially supported by Bayer AG.

**Conflict of Interest:** Andreas Schuppert holds a minor, part-time position at Bayer AG. Bayer AG had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## References

- Aben,N. *et al.* (2016) TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types. *Bioinformatics*, **32**, i413–i420.
- Barretina,J. *et al.* (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, **483**, 603–607.
- Basu,A. *et al.* (2013) An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. *Cell*, **154**, 1151–1161.
- Byers,L.A. *et al.* (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clin. Cancer Res.*, **19**, 279–290.
- Cancer Cell Line Encyclopedia Consortium and Genomics of Drug Sensitivity in Cancer Consortium (2015) Pharmacogenomic agreement between two cancer cell line data sets. *Nature*, **528**, 84–87.

- Chang, J.C. *et al.* (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. *J. Clin. Oncol.*, **23**, 1169–1177.
- Daemen, A. *et al.* (2013) Modeling precision treatment of breast cancer. *Genome Biol.*, **14**, R110.
- Dorman, S.N. *et al.* (2016) Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. *Mol. Oncol.*, **10**, 85–100.
- Gao, H. *et al.* (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat. Med.*, **21**, 1318–1325.
- Garnett, M.J. *et al.* (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature*, **483**, 570–575.
- Geeleher, P. *et al.* (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. *Genome Biol.*, **15**, R47.
- Huang, C. *et al.* (2017) Open source machine-learning algorithms for the prediction of optimal cancer drug therapies. *PLoS One*, **12**, 1–14.
- Jang, I.S. *et al.* (2014) Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. *Biocomputing*, **2014**, 63–74.
- Koti, M. *et al.* (2013) Identification of the IGF1/PI3K/NF  $\kappa$ B/ERK gene signaling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. *BMC Cancer*, **13**, 549.
- Luna, A. *et al.* (2016) rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. *Bioinformatics*, **32**, 1272–1274.
- Mulligan, G. *et al.* (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. *Blood*, **109**, 3177–3188.
- Rees, M. *et al.* (2016) Correlating chemical sensitivity and basal gene expression reveals mechanism of action. *Nat. Chem. Biol.*, **12**, 109.
- Seashore-Ludlow, B. *et al.* (2015) Harnessing connectivity in a large-scale small-molecule sensitivity dataset. *Cancer Discov.*, **5**, 1210–1223.
- Silver, D.P. *et al.* (2010) Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. *J. Clin. Oncol.*, **28**, 1145–1153.
- Smirnov, P. *et al.* (2016) PharmacoGx: an R package for analysis of large pharmacogenomic datasets. *Bioinformatics*, **32**, 1244–1246.
- Witkiewicz, A.K. *et al.* (2016) Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. *Cell Rep.*, **16**, 2017–2031.